ACURA PHARMACEUTICALS, INC 8-K

What Happened Acura Pharmaceuticals filed an 8-K on January 20, 2026 disclosing that it received three loans of $100,000 each from Abuse Deterrent Pharma, LLC on December 31, 2025, January 2, 2026 and January 16, 2026. These advances, together with prior loans and the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, result in a principal balance of $9,594,279 and accrued interest of approximately $980,000 as of January 15, 2026. The note bears interest at 5.25% (7.5% on overdue amounts) and includes standard events of default such as bankruptcy and failure to pay when due.

Key Details

• Three new loans: $100,000 each on Dec 31, 2025; Jan 2, 2026; Jan 16, 2026 (total $300,000).
• Secured note principal now $9,594,279; accrued interest ≈ $980,000 (as of Jan 15, 2026).
• Interest rate: 5.25% annually; default interest: 7.5% on overdue amounts.
• Company warned it needs additional financing by end of January 2026 or must scale back operations, furlough/lay off staff, or seek bankruptcy protection; could result in complete loss of shareholder value. Also noted upcoming June 30, 2026 dates related to FDA acceptance and payoff obligations under its agreement with Abuse Deterrent Pharma.

Why It Matters The filing documents a material increase in secured debt and a very short financing runway. The company is using the funds for day-to-day operations but explicitly warns that failure to obtain additional financing soon could force major cutbacks or bankruptcy, which would be highly dilutive or could eliminate shareholder value. Investors should view this as a liquidity and solvency risk and watch for follow-up financing, renegotiation of note terms, or operational changes. The company also included standard forward-looking statement disclosures about risks and uncertainties.